Launch prices are rising faster than prices for existing drugs, according to research by the drug price watchdog 46Brooklyn, and that’s bad news for Democrats, who recently changed their drug pricing bill to prevent Medicare from negotiating launch prices. The weighted average price per claim for brand drugs rose 58% in Medicaid from 2019 to 2021, compared to the 5% weighted average price increase for existing drugs, and a 46Brooklyn report says launch prices largely account for that difference. For...